Dr. Zandberg on the Role of Durvalumab in Head and Neck Cancer

Dan Zandberg, MD
Published: Friday, Oct 13, 2017



Dan Zandberg, MD, assistant professor of Medicine, the University of Maryland Medical Center, discusses the role of durvalumab (Imfinzi) in patients with metastatic head and neck cancer.

The phase II HAWK trial investigated durvalumab in patients with metastatic head and neck cancer who were PD-L1 high, states Zandberg. Promising outcomes were seen with an overall response rate (ORR) of 16% and durable response of 55%. The median overall survival was 7 months with a 1-year survival of 33%.

Overall the HAWK trial shows promising results, states Zandburg, and physicians are anxiously awaiting results from the ongoing phase III trial.



Dan Zandberg, MD, assistant professor of Medicine, the University of Maryland Medical Center, discusses the role of durvalumab (Imfinzi) in patients with metastatic head and neck cancer.

The phase II HAWK trial investigated durvalumab in patients with metastatic head and neck cancer who were PD-L1 high, states Zandberg. Promising outcomes were seen with an overall response rate (ORR) of 16% and durable response of 55%. The median overall survival was 7 months with a 1-year survival of 33%.

Overall the HAWK trial shows promising results, states Zandburg, and physicians are anxiously awaiting results from the ongoing phase III trial.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Vignette Series: 34th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow®Feb 28, 20182.0
Community Practice Connections™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations Across Lung, Head and Neck, and Bladder CancersApr 28, 20182.0
Publication Bottom Border
Border Publication
x